To the full analysis
Buyback calculator for Madrigal Pharmaceuticals
Madrigal Pharmaceuticals stock: key metrics
MDGLMadrigal Pharmaceuticals had an operating margin of −31.3% and a return on invested capital (ROIC) of −26% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | no data | no data | no data |
| 2007 | 0.0% | −8,912.0% | −8,545.8% |
| 2008 | 0.0% | −3,583.5% | −3,541.8% |
| 2009 | 97.4% | 55.8% | 54.8% |
| 2010 | 0.0% | −249.3% | −253.1% |
| 2011 | 80.7% | −599.1% | −624.7% |
| 2012 | no data | no data | no data |
| 2013 | no data | no data | no data |
| 2014 | no data | no data | no data |
| 2015 | no data | no data | no data |
| 2016 | no data | no data | no data |
| 2017 | no data | no data | no data |
| 2018 | no data | no data | no data |
| 2019 | no data | no data | no data |
| 2020 | no data | no data | no data |
| 2021 | no data | no data | no data |
| 2022 | no data | no data | no data |
| 2023 | no data | no data | no data |
| 2024 | 96.5% | −276.4% | −258.6% |
| 2025 | 94.1% | −31.3% | −30.1% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | 200.0% | no data | −100.0% |
| 2007 | −100.0% | −69.8% | −51.8% |
| 2008 | 157.5% | −86.9% | −95.2% |
| 2009 | 200.0% | 163.5% | 161.7% |
| 2010 | −100.0% | −83.6% | −69.3% |
| 2011 | −100.0% | no data | −100.0% |
| 2012 | −83.6% | −81.2% | −61.0% |
| 2013 | −100.0% | −86.5% | −94.7% |
| 2014 | −100.0% | −87.5% | −85.6% |
| 2015 | −13.6% | −3.4% | −10.0% |
| 2016 | −72.5% | −37.8% | −64.0% |
| 2017 | −17.1% | −23.0% | −16.2% |
| 2018 | −6.9% | −9.7% | −6.8% |
| 2019 | −20.2% | −16.8% | −19.0% |
| 2020 | −84.3% | −49.6% | −70.5% |
| 2021 | −100.0% | −87.7% | −88.5% |
| 2022 | −100.0% | no data | −81.5% |
| 2023 | −92.2% | −78.2% | −58.3% |
| 2024 | −61.8% | −56.4% | −44.7% |
| 2025 | −47.8% | −26.0% | −22.9% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Nov 2010)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.